DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

Completed

• Conditions: Lung Cancer; Bladder Cancer; Kidney Cancer; Colorectal Cancer; Liver Cancer; Head and Neck Cancer; Esophageal Cancer; Pancreas Cancer; Skin Cancer; Stomach Cancer

• Registration Number: NCT04825834
• Lead Sponsor: Delfi Diagnostics Inc.

Brief Summary

The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.

Detailed Description

Subjects will be enrolled into the DELFI-L101 study after informed consent and eligibility is confirmed. At enrollment, subjects will have blood specimens collected (\~40 mL) and 12 months post-enrollment their medical records will be reviewed.

Study Timeline

• Study Start: 2021-03-22
• Study First Submitted: 2021-03-29
• Study First Submitted QC: 2021-03-30
• Study First Posted: 2021-04-01
• Primary Completion: 2025-07-15
• Study Completion: 2025-07-15
• Status Verified: 2025-08
• Last Update Submitted: 2025-08-05
• Last Update Posted: 2025-08-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2992

Inclusion Criteria

All Participants:

1. Ability to understand and provide written informed consent

2. Age ≥ 50 years

3. Current or Former Smoker

4. ≥ 20 pack-years (pack years = number of packs per day X number of years smoked)

   Inclusion Group 1: High Risk Patients that meet criteria 5 and 6 below:

5. Prior thoracic imaging with computed tomography (CT) within 12 months of enrollment (CT imaging for lung cancer screening for participants meeting inclusion criteria 6a and 6b; or CT imaging for lung cancer screening or diagnostic CT for participants meeting inclusion criteria 6c)

   OR Planned thoracic imaging (CT) as part of standard of care within 6 weeks of enrollment (CT imaging for lung cancer screening for participants meeting inclusion criteria 6a and 6b; or CT imaging for lung cancer screening or diagnostic CT for participants meeting inclusion criteria 6c)

   AND

6. Meet one of the criteria below:

   1. No suspected or confirmed lung cancer diagnosis OR
   2. Suspected of lung cancer OR
   3. Confirmed, untreated lung cancer

   Inclusion Group 2: High Risk Patients that meet the following criteria:

7. Pathologic confirmed, invasive non-lung cancer diagnosis, originating from the esophagus (upper), colon or rectum, pancreas, stomach (including lower esophagus), head and neck, skin (excluding cutaneous basal cell and squamous cell carcinoma) kidney, or liver, with no prior systemic therapy, definitive therapy, radiation, or surgical resection.

OR Clinically confirmed invasive non-lung cancer diagnosis originating from the pancreas, kidney, or liver, based on imaging and clinical judgment with planned treatment and no prior systemic therapy, definitive therapy, radiation, or surgical resection.

OR Clinically (based on imaging and clinical judgment) or pathologically confirmed non-invasive or invasive bladder cancer with planned treatment and no prior systemic therapy, definitive therapy, radiation or surgical resection.

Exclusion Criteria

All Participants:

1. Prior systemic therapy, definitive therapy, radiation, or surgical resection for cancer within one year prior to enrollment (with the exception of organ biopsies or surgery for non-melanoma skin cancer)
2. Any history of hematologic malignancies or myelodysplasia
3. Any history of organ tissue transplantation
4. Any history of blood product transfusion
5. Current pregnancy
6. Any condition that in the opinion of the Investigator should preclude the participant's participation in the study
7. Prior systemic therapy, definitive therapy, radiation, or surgical resection for the enrollment cancer diagnosis (with the exception of organ biopsies or surgery for non-melanoma skin cancer are not exclusionary)
8. Enrollment in any DELFI sponsored study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Accuracy of lung cancer detection measured by sensitivity, specificity, and the AUC of the ROC.	Approximately 12 months

Secondary Outcome Measures

Name	Time	Method
Accuracy (sensitivity and specificity) in clinical subgroups of interest	Approximately 12 months
Analytical performance (e.g. repeatability/reproducibility)	Approximately 12 months
Accuracy of multi-cancer detection measured by sensitivity, specificity, and the AUC of the ROC and tissue of origin (TOO) accuracy	Approximately 12 months
Prevalence-based measures, including positive predictive value (PPV), negative predictive value (NPV), and number needed to screen (NNS)	Approximately 12 months
Accuracy of tumor of origin (confusion matrix of predicted versus actual cancer type)	Approximately 12 months
Adverse events (AEs) associated with the blood specimen collection	Point in time of blood specimen collection (1day) at enrollment
Expected distribution of the DELFI score in the intended use population and clinical subgroups of interest	Approximately 12 months
Association of genomic features with clinical subgroups of interest	Approximately 12 months

Trial Locations

Locations (56)

Central Alabama Research; 🇺🇸 Homewood, Alabama, United States

Phoenix Medical Group; 🇺🇸 Peoria, Arizona, United States

Highlands Oncology Group - Fayetteville; 🇺🇸 Fayetteville, Arkansas, United States

Pulmonary Associates of Burlingame; 🇺🇸 Burlingame, California, United States

Kaiser Permanente Los Angeles Medical Center; 🇺🇸 Los Angeles, California, United States

Torrance Memorial Physician Network - Cancer Care; 🇺🇸 Torrance, California, United States

Centura Health; 🇺🇸 Colorado Springs, Colorado, United States

National Jewish Health; 🇺🇸 Denver, Colorado, United States

St. Mary's Hospital and Regional Medical; 🇺🇸 Grand Junction, Colorado, United States

Starling Physicians; 🇺🇸 New Britain, Connecticut, United States

Scroll for more (46 remaining)